Corteva (NYSE:CTVA) SVP Cornel B. Fuerer purchased 2,000 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were acquired at an average price of $26.13 per share, for a total transaction of $52,260.00.
CTVA traded up $0.12 during trading on Friday, hitting $26.28. The stock had a trading volume of 881,983 shares, compared to its average volume of 4,675,158. Corteva has a 12 month low of $24.35 and a 12 month high of $32.78. The company has a 50 day simple moving average of $26.87.
Corteva (NYSE:CTVA) last announced its earnings results on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.07. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.97 billion. The company’s revenue was down 1.8% on a year-over-year basis. As a group, equities research analysts forecast that Corteva will post 1.24 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Friday, November 29th will be issued a $0.13 dividend. The ex-dividend date is Wednesday, November 27th. This represents a $0.52 annualized dividend and a yield of 1.98%.
A number of research analysts have recently weighed in on CTVA shares. Barclays set a $32.00 price target on shares of Corteva and gave the company a “hold” rating in a report on Friday, November 1st. Citigroup cut their price target on shares of Corteva from $34.50 to $31.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Monness Crespi & Hardt started coverage on shares of Corteva in a report on Wednesday, July 17th. They set a “sell” rating and a $24.00 price target on the stock. Deutsche Bank raised their price target on shares of Corteva from $32.00 to $35.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. downgraded shares of Corteva from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $30.00 to $27.00 in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $31.50.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Litman Gregory Asset Management LLC acquired a new stake in Corteva in the 2nd quarter worth $26,000. Catalyst Capital Advisors LLC grew its position in Corteva by 261.2% in the 3rd quarter. Catalyst Capital Advisors LLC now owns 939 shares of the company’s stock worth $26,000 after purchasing an additional 679 shares during the last quarter. Executive Wealth Management LLC acquired a new stake in Corteva in the 2nd quarter worth $27,000. Acima Private Wealth LLC acquired a new stake in Corteva in the 3rd quarter worth $27,000. Finally, Roble Belko & Company Inc acquired a new stake in Corteva in the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 72.44% of the company’s stock.
Corteva, Inc provides agriculture products worldwide. The company develops and supplies germplasm and traits in corn, soybean, and sunflower seed markets. It also supplies products to the agricultural input industry that protect against weeds, insects and other pests, and diseases, as well as to enhance crop health.
Read More: Buyback
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.